CING - Wutah pendapatan YoY sajrone 12 wulan kepungkur Cingulate Inc.

Experts value Cingulate Inc. (CING) for its innovative approach to ADHD treatment. Analyzing the chart on GURU.Markets, we find that the trailing twelve months (TTM) annual growth in operating sales revenue has reached a level where the 0.00 mark records this indicator. The company relies on the CTRX platform with a unique substance release profile, yet it faces pressure from low-cost generics and a fierce struggle for insurance reimbursements.

Wutah dodolan YoY sajrone rolas wulan kepungkur: cingulate.com (CING) kanggo 11.02.2024 - 15.11.2026

Cingulate Inc - rincian analitis lan metrik utama (CING)

- nilai pasar lan prakiraan target analis:

Rega bursa Cingulate Corp|CING - Prakiraan konsensus analis

- statistik kapitalisasi pasar:

Biji pasar Cingulate Inc.|CING - Nilai Perusahaan

- data nilai buku modal saham:

Aset Bersih saben Saham Cingulate|CING - Nilai Buku Perusahaan|Rasio Kapitalisasi marang Nilai Buku cingulate.com|CING - Total Aset Perusahaan

- rincian struktur utang lan likuiditas bisnis:

- indikator profitabilitas perusahaan lan kelipatan valuasi:

CING - Bathi resik|Bathi resik sing dikarepake Cingulate Inc.|CING - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi Cingulate Corp|CING - Pangali PEG|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan Cingulate Inc|CING - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajrone 12 wulan pungkasan Cingulate|CING - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan cingulate.com|CING - Wutah bathi resik saben saham ing taun iki|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Cingulate Inc.

- data dodolan lan asil:

CING - Pendapatan lan volume dodolan|Volume dodolan mangsa ngarep perusahaan Cingulate Corp|CING - Multiplikator P/S|Rasio kapitalisasi marang dodolan sing dikarepake Cingulate Inc|CING - Wutah dodolan YoY sajrone rolas wulan kepungkur

Analisis kabeh metrik perusahaan:cingulate.com (CING)

Cingulate Inc. faces a critical liquidity shortage and regulatory risks in the development of ADHD medications. This indicator captures the consensus estimate of revenue growth rates over the last twelve months relative to the previous year. The metric allows for a real-time assessment of cash flow stagnation, which is critical when dependent on secondary offerings. It is essential for investors to correlate this data with the debt load. Analyzing the TTM year-over-year product sales dynamics provides an objective measure of business sustainability.

Karo sapa Cingulate Inc. saingan

Alkermes Inc. (ALKS) - Wutah pendapatan taun lumaku|Avadel Corp - Wutah dodolan YoY (TTM)|ATAI - Wutah dodolan YoY (TTM)|GHRS: Wutah dodolan YoY (TTM)|MNMD - Wutah pendapatan taunan sajrone rolas wulan kepungkur|Wutah dodolan YoY sajrone rolas wulan kepungkur COMPASS Corp|LBRX: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY (TTM) DRUG|Vanda Pharmaceuticals - Wutah dodolan YoY sajrone 12 wulan kepungkur|Wutah dodolan YoY sajrone rolas wulan kepungkur cybin.com CYBN|Dinamika pendapatan YoY sajrone rolas wulan kepungkur ANRO|NRx Pharma - Wutah dodolan YoY (TTM)|Wutah dodolan taun lumaku SILO|China Pharma Holdings, Inc. (CPHI) - Wutah dodolan YoY sajrone rolas wulan kepungkur|CMND - Wutah pendapatan taunan sajrone rolas wulan kepungkur|PBM (Psyence Biomedical) - Wutah dodolan YoY (TTM)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Clearmind Medicine (SPRC)|Wutah dodolan YoY (TTM) SEEL|VRPX (Virpax Pharmaceuticals, Inc.) - Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY (TTM) KRTX (Karuna Therapeutics Inc)